Genome Editing Market Summary

The global genome editing market size was estimated at USD 9.78 billion in 2024 and is projected to reach USD 40.59 billion by 2033, growing at a CAGR of 17.0% from 2025 to 2033. This substantial growth is driven by the successful outcomes in preclinical models, which have significantly increased the demand for genome editing therapeutics. Additionally, rising competition among market participants is accelerating business development activities, while continuous technological advancements in gene editing platforms are enhancing the efficiency, precision, and safety of these techniques. The increasing adoption of genome editing technologies in agricultural biotechnology is further contributing to the expansion of the market globally.

The COVID-19 pandemic had a considerable impact on the genome editing market, causing disruptions in clinical trials, supply chains, and regulatory processes. Lockdowns, travel restrictions, and workforce limitations affected manufacturing and distribution, leading to delays in the production and delivery of gene therapy products. Despite these challenges, companies in the industry have implemented adaptive strategies, including remote monitoring, digital workflows, and accelerated R&D initiatives, which are helping the market recover steadily. The pandemic also acted as a catalyst for innovation, particularly in gene alteration technologies, driven by the urgent need for effective COVID-19 treatments and vaccines. For instance, researchers at Nanyang Technological University developed the VaNGuard (Variant Nucleotide Guard) diagnostic test in March 2021, which is capable of detecting SARS-CoV-2 strains with mutations, demonstrating the potential of CRISPR genome editing technology for rapid diagnostics.

Key Market Trends & Insights

  Regional Market Share: North America dominated the global genome editing market, accounting for a 44.59% share in 2024, largely due to significant investments in research and development of gene editing technologies.

  Country-Level Insight: Within North America, the United States held the largest market share, reflecting its robust infrastructure and well-established biotech ecosystem.

  Technology Segment: The CRISPR/Cas9 segment led the global market, representing 44.36% of the total revenue in 2024, highlighting its widespread adoption, versatility, and reliability across multiple applications.

  Application Segment: Genetic engineering emerged as the largest application segment, contributing significantly to market growth in 2024 due to its transformative potential in therapeutics and agriculture.

  End-Use Segment: Biotechnology and pharmaceutical companies accounted for the largest share of 50.71% in 2024, underscoring their central role in driving innovation and commercialization of genome editing solutions.

Order a free sample PDF of the Genome Editing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 9.78 Billion
• 2033 Projected Market Size: USD 40.59 Billion
• CAGR (2025-2033): 17.0%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

Key players operating in the genome editing market are undertaking various initiatives to strengthen their market presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are playing a key role in propelling the market growth.

Key Players

• Merck KGaA
• Takara Bio Inc.
• Revvity, Inc.
• Danaher Corporation
• GenScript
• New England Biolabs
• Lonza
• Thermo Fisher Scientific, Inc.
• Charles River Laboratories
• Eurofins Scientific

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global genome editing market is poised for remarkable growth over the next decade, driven by advancements in gene editing technologies, increasing applications in therapeutics and agriculture, and substantial investments in research and development. Despite challenges posed by the COVID-19 pandemic, the industry has demonstrated resilience and adaptability, implementing innovative strategies and accelerating R&D initiatives. With the widespread adoption of CRISPR/Cas9 and other advanced genome editing platforms, biotechnology and pharmaceutical companies are expected to continue leading the market. This growth trajectory highlights the transformative potential of genome editing in improving human health and agricultural productivity worldwide.